Shanghai Best-Link Bioscience, LLC, a leading nano drug and drug delivery-focused enterprise based in Shanghai, has reportedly raised close to RMB 200 million (USD 29 million) in a Series A financing round. The funding round was led by Lapam Capital, with significant contributions from Hui Ding Capital and TigerYeah Capital. The proceeds from this investment will be directed towards pre-clinical research and development, IND filing, Phase I clinical trials, and the expansion of the company’s technology platforms.
Building on Innovative Nanotechnology Platforms
Founded in 2021, Best-Link Bioscience has quickly established itself as a pioneer in the field of nanotechnology with a suite of advanced platforms. These include a drug coupling self-assembly nanotechnology platform, a small molecule-small molecule self-assembly nanotechnology platform, and a nano drug continuous intelligent manufacturing platform. These technologies position Best-Link Bioscience at the forefront of innovation in personalized medicine and targeted drug delivery systems.
Expanding Research and Development Efforts
The capital raised in the Series A financing round will be instrumental in accelerating Best-Link Bioscience’s pre-clinical research and development efforts. It will also support the company’s IND filing process and the initiation of Phase I clinical trials, which are critical milestones in the journey to bringing new nano drug solutions to market. Furthermore, the funds will be used to expand the company’s technology platforms, enhancing its capabilities in nano drug manufacturing and drug delivery.-Fineline Info & Tech
